Compare Centene Corp (CNC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Summit Therapeutics Inc — how do they compare? Centene Corp trades at $65 (market cap $32.05B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Centene Corp is far larger — about 2.7× Summit Therapeutics Inc's market cap, and Centene Corp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CNC | SMMT | |
|---|---|---|
Market Cap | $32.05B | $12.06B |
Sector | Health | Health |
52-Week High | $68.72 | $26.98 |
52-Week Low | $26.17 | $12.55 |
Enterprise Value | $21.10B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $67.35, up 1.19% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock has beaten earnings estimates in recent quarters, including Q2 2026 EPS of $2.51 versus $1.09 expected, and shows robust cash flow trends with 2025 net cash flow of $3.94 billion. Recent news highlights margin recovery and raised 2026 guidance, reinforcing positive momentum.
The outlook remains favorable given valuation discounts (P/E of 8.06, P/S of 0.16) and analyst consensus price target of $71.00, though risks include negative net income margins and Medicaid membership volatility. Upside potential hinges on execution of cost controls and premium growth in government-sponsored health plans.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
